NICE recommends dabrafenib in final draft guidance
The National Institute for Health and Care Excellence has issued final draft guidance for consultation recommending the new skin cancer drug, dabrafenib. Appeals against the decision can be lodged until 2 October 2014.
Citation: The Pharmaceutical Journal DOI: 10.1211/PJ.2014.20066530
Recommended from Pharmaceutical Press
Commonly known as the Orange Guide, this book is an essential reference for all involved in the manufacture or distribution of medicines in Europe.£82.00Buy now
Pharmacy Registration Assessment Questions 2 features more than 400 entirely new, closed book and calculation questions. It can be used in conjunction with the previous volume or on its own. All questions are in line with current GPhC guidance, enabling you to prepare for the pharmaceutical pre-registration exam with confidence.£35.00Buy now